 |
|
Parental Tolerance of False-positive Newborn Screening Results
Lisa A. Prosser, MS, PhD;
Joseph A. Ladapo, PhD;
Donna Rusinak, BA;
Susan E. Waisbren, PhD
Arch Pediatr Adolesc Med. 2008;162(9):870-876.
Objective To measure parental tolerance for a false-positive newborn screening result by assessing perceived quality of life for screening results and health states associated with expanded newborn screening programs for metabolic disorders.
Design Perceived quality of life was measured using time trade-off and willingness-to-pay questions for a false-positive newborn screening result and other conditions associated with metabolic disorders (ie, short-term hospitalization, dietary treatments, and developmental delay).
Setting Telephone or in-person interviews were conducted from October 1, 2004, through January 31, 2006, for 2 populations in Massachusetts and Pennsylvania.
Participants Parents of children who had a false-positive newborn screening result (n = 91) and parents of children with normal screening results (n = 50).
Intervention Telephone interviews.
Main Outcome Measures Time trade-off and willingness-to-pay amounts.
Results Median time trade-off and willingness-to-pay amounts for parents of children with false-positive screening results were both 0 compared with parents of children with normal screening results who had median values of 1 week (P = .07) and $100 (P < .001). For both populations, dietary treatments and developmental delay elicited higher time trade-off and willingness-to-pay amounts compared with ratings for experiencing a false-positive newborn screening result or short-term hospitalization because of an undiagnosed metabolic disorder.
Conclusions Parents have a high tolerance for false-positive newborn screening results. Preferences for test outcomes and other health states associated with screening for metabolic disorders should be included in cost-effectiveness and cost-benefit analyses of expanded newborn screening programs.
Author Affiliations: Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care (Dr Prosser and Ms Rusinak), Program for Health Decision Science, Harvard School of Public Health (Dr Prosser), and Department of Psychiatry, Children's Hospital Boston (Dr Waisbren), Boston, Massachusetts; and PhD Program in Health Policy, Harvard University, Cambridge, Massachusetts (Dr Ladapo).
|
